ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Moreover, early reduction in BCR-ABL transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib and the reduction in BCR-ABL correlates with prognosis [15–17].